

Brief report

Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors

Mats Remberger, Dietrich W. Beelen, Axel Fauser, Nadezda Basara, Oliver Basu, and Olle Ringdén

The long-term follow-up of a study including 214 patients receiving either peripheral blood stem cells (PBSCs) or bone marrow (BM) from an HLA-A, -B, and -DR-compatible unrelated donor is presented. Median follow-up was 4.4 (2.3-7.3) and 5.0 (0.7-8.4) years in the 2 groups, respectively. Cumulative incidence of overall chronic graft-versus-host disease (GVHD) was similar in the 2 groups (78%

vs 71%), while extensive chronic GVHD was significantly more common in the PBSC group compared with the BM group (39% vs 24%, $P = .03$). The 5-year transplant-related mortality (TRM) was 37% in the PBSC group and 35% in the BM controls ($P = .7$), and overall survival was 42% in both groups. The relapse incidences were 26% and 27% in the 2 groups, respectively, resulting in a disease-free

survival of 41% in both groups. In conclusion, PBSCs from HLA-compatible unrelated donors results in similar outcome compared to BM but implies an increased risk for extensive chronic GVHD. (Blood. 2005;105:548-551)

© 2005 by The American Society of Hematology

Introduction

Only few patients have been reported who received peripheral blood stem cells (PBSCs) from unrelated donors.¹⁻³ Reasons for the reluctance to use PBSCs from unrelated donors have been the ethics of administering granulocyte colony-stimulating factor (G-CSF) to healthy volunteers and that the 10- to 15-fold higher donor T-cell content of PBSCs would increase the risk of graft-versus-host disease (GVHD). Some reports have indicated a higher incidence of chronic GVHD after sibling PBSCs.⁴⁻⁶ Previously we reported the initial results comparing PBSCs with BM from unrelated donors at 3 centres.² Here we report the long-term results.

Study design

Patients

The study group consisted of 107 consecutive patients who received PBSCs from unrelated donors between February 1993 and September 1999 (Table 1). Approval for this study was obtained from the institutional review board at Huddinge University Hospital and the local ethics committee at each center. Informed consent was provided according to the Declaration of Helsinki.

BM control group

For each unrelated PBSC transplant recipient, we selected a control who had received unrelated bone marrow (BM) at almost the same time. Controls were matched for diagnosis, stage of disease, age (< 20 years or > 20 years) and GVHD prophylaxis. No difference between the 2 groups existed except that slightly more patients in the BM group received total body irradiation (TBI)-based conditioning (84% vs 70%, $P = .03$).

Donors

All donors were HLA-A, -B and -DRβ1 compatible with the patients. Before 1997, class I HLA typing was serological. Since then, polymerase chain reaction-sequence-specific-primer (PCR-SSP) low-resolution typing for class I was used. For HLA class II, genomic high resolution DNA-based typing (PCR-SSP) was used.⁷ All patients from Huddinge ($n = 64$) were retyped using PCR-SSP for HLA class I (A, B, and C) and II (DR, DP, and DQ).⁸

Conditioning

Most patients received cyclophosphamid (Cy) 120 mg/kg, combined with TBI, dose ranging from 10 to 13.5 Gy (Table 1).

Thirty-eight patients were given busulfan (Bu) 16 mg/kg followed by 120 mg/kg Cy. Detailed description of the therapy and care is given elsewhere.^{1,9,10}

GVHD prophylaxis

The most common immunosuppression was cyclosporine A (CsA) and 4 doses of methotrexate (MTX) (Table 1). Twelve patients did not receive MTX as part of GVHD prophylaxis.

Graft-versus-host disease

Chronic GVHD was defined as limited or extensive according to standard criteria.¹¹

Statistics

Analysis was performed on December 10, 2003.

From the Centre for Allogeneic Stem Cell Transplantation and Department of Clinical Immunology, Karolinska University Hospital, Stockholm, Sweden; the Department of Bone Marrow Transplantation, University Hospital Essen, Germany; the Clinic of BMT, Haematology and Oncology, Idar-Oberstein, Germany; and the Department of Paediatric Haematology, Oncology and Endocrinology, University Hospital Essen, Germany.

Submitted March 17, 2004; accepted September 1, 2004. Prepublished online as *Blood* First Edition Paper, September 14, 2004; DOI 10.1182/blood-2004-03-1000.

Supported by grants from the Swedish Cancer Society (0070-B02-16XAC), the

Children's Cancer Foundation (2002/074), the Swedish Research Council (K03-32X-05971-23A), the Cancer Society in Stockholm (02:181), and the Tobias Foundation.

Reprints: Mats Remberger, Department of Clinical Immunology, F79, Karolinska University Hospital, SE-141 86 Stockholm, Sweden; e-mail: mats.remberger@labmed.ki.se.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

© 2005 by The American Society of Hematology

Table 1. Patients' and donors' characteristics, conditioning, and GVHD prophylaxis

	PBSC Group	BM Group
No. patients	107	107
Recipient age, y (range)	35 (5-56)	37 (1-55)
Donor age, y (range)	33 (20-53)	36 (18-55)
Sex		
Recipient		
No. male	56	60
No. female	51	47
Donor		
No. male	72	62
No. female	35	44
Diagnoses		
Acute myeloid leukemia		
Early disease, no.	12	11
Late disease, no.	24	24
Acute lymphocytic leukemia		
Early disease, no.	5	7
Late disease, no.	11	10
Chronic myeloid leukemia		
CP, no.	43	43
AP, no.	6	6
BC, no.	2	3
Lymphoma, no.	1	0
Myelodysplastic syndrome, no.	2	2
Aspartylglycosaminuria, no.	1	1
Recipient CMV serology, (-/+)	43/64	47/59
Donor CMV serology (-/+)	61/46	58/48
Conditioning		
TBI containing, no. (%)	75 (70%)	90 (84%)
Busulfan containing, no.	31 (29%)	17 (16%)
No. ATG/OKT-3	25/11	21/16
GVHD prophylaxis		
CsA or MTX, no.	2	3
CsA + prednisolone, no.	3	3
CsA + MMF ± pred, no.	3	0
CsA + MTX ± pred, no.	96	100
CsA + MTX ± pred + MMF, no.	3	1
Follow-up, y (range)	4.4 (2.3-7.3)	5.0 (0.7-8.4)

Absolute numbers or median and range are given.

Early indicates CR1; Late, > CR1; CP, chronic phase; AP, accelerated phase; BC, blast crisis; TBI, total body irradiation; CsA, cyclosporine; MTX, methotrexate; MMF, mycomofetilphenolate; and Pred, prednisolone.

Separate statistical analyses were performed for each end point (relapse, transplant-related mortality [TRM], disease-free survival [DFS], and chronic GVHD). Overall survival and disease-free survival were calculated with the Kaplan-Meier method,¹² comparing the groups using the log-rank test (Mantel-Haentzel).¹³ The incidence of TRM, relapse, and chronic GVHD were estimated using a nonparametric estimator of cumulative incidence curves. The Cox regression model was used to analyze predictive factors for chronic GVHD, TRM, survival, relapse, and DFS.¹⁴

In analyzing risk factors for relapse and chronic GVHD, only patients surviving more than 90 days after transplantation were included. Four patients relapsed before day 90 and were included in the risk factor analysis of relapse. Factors significant at the 10% level in the univariate analysis

were included in the multivariate analysis. The following factors were analyzed: methotrexate, nucleated cell dose, CD34 dose, patient and donor age and sex, antithymocyte globulin (ATG), granulocyte colony-stimulating factor (G-CSF) after transplant, stem cell source, disease, disease stage, pretransplant cytomegalovirus (CMV) serology, conditioning, and GVHD.

Results and discussion

PBSC grafts versus BM grafts showed faster engraftment of neutrophils and platelets, which was presented previously.² In this long-term follow-up we found no difference in overall chronic GVHD: 78% and 71% in patients receiving PBSCs and BM grafts, respectively. This is in accordance with other studies with unrelated donors.¹⁻³

Using HLA-identical sibling donors, some studies have reported a higher incidence of overall chronic GVHD when using PBSCs.⁴⁻⁶ The reason for absence of a difference may be the higher incidence of chronic GVHD using unrelated donors compared to HLA-identical siblings.^{15,16}

As previously reported, chronic myeloid leukemia (CML) and acute GVHD were correlated to chronic GVHD.¹⁷ We also found that patients not receiving ATG had more chronic GVHD. Absence of ATG is correlated to more acute GVHD, and acute GVHD triggers chronic GVHD.¹⁷

Extensive chronic GVHD was more common in the PBSC group compared with the BM group (39% vs 24%, $P = .03$) (Figure 1). This has previously been reported using sibling donors⁴ but not with unrelated donors. In multivariate analysis GVHD grades II-IV (RH 1.88, CI 1.07-3.29, $P = .03$) and PBSC (RH 1.73, CI 1.00-3.00, $P < .05$) were correlated to extensive chronic GVHD. As acute GVHD triggers chronic GVHD, it is logical to assume that more severe acute GVHD triggers more severe chronic GVHD. This was previously shown.¹⁸ Some information on patients with extensive chronic GVHD is displayed in Table 2.

TRM was 28% and 29% at 1 year and 37% and 35% at 5 years in the PBSC and BM groups, respectively. This is in line with previous studies with related and unrelated donors. Acute GVHD is one of the main causes for TRM, and most studies comparing PBSCs and BM showed similar incidence of acute GVHD.

In the multivariate analysis, acute GVHD grades II-IV (RH 6.05, CI 3.67-9.97, $P < .001$), patient age (RH 1.34, CI 1.09-1.63, $P = .007$), and absence of MTX as GVHD prophylaxis (RH 3.10, CI 1.28-7.46, $P = .012$) were independent risk factors for TRM.

The 5-year probability of survival was 42% in both groups. Among patients with early disease (CR1/CP1), the probability of survival was 56% and 54%, and for patients in later stages it was 24% and 26% in the PBSC and the BM group, respectively (not statistically significant [ns]).

Primary causes of death were relapse in 19 and 25, infection in 17 and 13, GVHD in 18 and 13, and other causes, 6 and 10 in the PBSC and BM group, respectively (ns). In the multivariate analysis, absence of chronic GVHD (RH 3.29, CI 1.99-5.42

Table 2. Bilirubin, platelet levels, and immunosuppression in patients with extensive chronic GVHD after PBSC and BMT

	No.	Bilirubin, μmol/L (range)	Platelets, ×10 ⁹ /L (range)	Response to prednisolone, no.			Immunosuppression status, no.		Time to cessation of IS, d after cGVHD (range)
				None	Partial	Full	Stopped	Not stopped	
PBSC	31	15 (5-255)	137 (9-300)	12	8	11	8	23	963 (405-2182)
BM	19	16 (4-134)	166 (25-300)	4	5	10	5	14	1265 (526-2096)

PBSC indicates peripheral stem-cell transplantation; BMT, bone marrow transplantation; and IS, immunosuppression. P was not significant for any of the variables.

$P < .001$), late disease (RH 2.32, CI 1.49-3.60, $P < .001$), and acute GVHD II-IV (RH 2.34, CI 1.42-3.86, $P < .001$) were independent risk factors for death.

The cumulative incidence of relapse was 26% and 27% in the PBSC and BM groups, respectively. Among patients with early disease the 5-year incidence of relapse was 9% and 15%, and for patients in late disease it was 37% in both groups (ns).

In the multivariate analysis, advanced disease (RH 4.05, CI 2.03-8.08, $P < .001$), absence of chronic GVHD (RH 3.22, CI 1.77-5.87, $P < .001$), and non-CML diagnoses (RH 2.25, CI 1.04-4.85, $P = .037$) were independent risk factors for relapse. Using unrelated donors, the incidence of chronic GVHD is higher than in HLA-identical siblings, which also carries a graft-versus-leukemia effect,^{19,20} thus reducing the risk of relapse.

DFS at 5 years was 41% in both groups. Among patients with CML, DFS was 57% and 52% in the PBSC and the BM groups, respectively. Corresponding figures for patients with acute leukemia was 26% and 31% (ns).

Two studies and a meta-analysis demonstrated a survival advantage with PBSC limited to patients with advanced disease.²¹⁻²³ In our material, we found no difference in DFS among patients given PBSC or BM with CML or acute leukemia with early or late disease.

However, among patients not in remission at transplantation ($n = 33$), we found a trend for a better OS and DFS (24% vs 11%, $P = .11$) in patients receiving PBSCs compared with BM. However, the number of patients is small.

In the multivariate analysis, chronic GVHD (RH 3.42, CI 2.14-5.47, $P < .001$), early disease (RH 2.66, CI 1.72-4.14, $P < .001$), and acute GVHD 0-I (RH 1.80, CI 1.13-2.89, $P = .016$) were independent prognostic factors for a better DFS.

Factors associated with a better DFS in our study agree with other studies.^{24,25}




Figure 1. Cumulative incidence of extensive chronic GVHD. Time to and cumulative incidence of extensive chronic GVHD after unrelated donor stem cell transplantation with peripheral blood stem cells (PBSCs) or bone marrow (BM).

With regard to TRM, survival, relapse, and disease-free survival, the outcome was the same in patients receiving PBSCs or BM. This accords with most reports comparing PBSCs with BM using related or unrelated donors,^{1,2,4,6,26} while a study from European Group for Blood and Marrow Transplantation (EBMT) showed better outcome with rich bone marrow.²⁷

In conclusion, this study has shown that the use of PBSCs from unrelated donors is a safe and well-tolerated procedure, but the risk for extensive chronic GVHD is increased.

Acknowledgments

We would like to thank all nurses at the departments for excellent and skillful care and all volunteer donors for their generous gifts to the patients.

References

- Blau IW, Basara N, Lentini G, et al. Feasibility and safety of peripheral blood stem cells transplantation from unrelated donors: results of a single center study. *Bone Marrow Transplant*. 2001;27:27-33.
- Remberger M, Ringdén O, Blau I, et al. No difference in graft-versus-host disease, relapse and survival comparing peripheral stem cells to bone marrow using unrelated donors. *Blood*. 2001;98:1739-1745.
- Garderet L, Labopin M, Gorin NC, et al. Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow. *Bone Marrow Transplant*. 2003;31:23-29.
- Mothy M, Kuentz M, Michallet M, et al. Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. *Blood*. 2002;100:3128-3134.
- Ringdén O, Labopin M, Bacigalupo A, et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukaemia and acute lymphoblastic leukaemia. *J Clin Oncol*. 2002;24:4655-4664.
- Schmitz N, Beksac M, Hasenclever D, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard risk leukaemia. *Blood*. 2002;100:761-767.
- Olerup O, Zetterqvist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. *Tissue Antigens*. 1992;39:225-235.
- Schaffer M, Aldener-Cannavà A, Remberger M, Ringdén O, Olerup O. Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome in unrelated stem cell transplantation. *Tissue Antigens*. 2003;62:243-250.
- Ringdén O, Remberger M, Persson U, et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. *Bone Marrow Transplantation*. 1995;15:619-625.
- Beelen DW, Ottinger HD, Elmaagacli A, et al. Transplantation of filgrastim-mobilized peripheral blood stem cells from HLA-identical sibling or alternative family donors in patients with hematologic malignancies: a prospective comparison on clinical outcome, immune reconstitution, and hematopoietic chimerism. *Blood*. 1997;90:4725-4735.
- Shulman H, Sullivan K, Weiden P, et al. Chronic graft-versus-host syndrome in man: a clinicopathological study of 20 long-term Seattle patients. *Am J Med*. 1980;69:204-217.
- Kaplan E, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc*. 1958;53:457-481.
- Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II: analysis and examples. *Br J Cancer*. 1977;35:1-39.
- Cox D. Regression models and life-tables. *J R Stat Soc (Series B)*. 1972;34:187-220.
- Beatty P, Hansen J, Longton G, et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. *Transplantation*. 1991;51:443-447.
- Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. *N Engl J Med*. 1993;328:593-602.
- Carlens S, Ringdén O, Remberger M, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. *Bone Marrow Transplant*. 1998;22:755-761.
- Remberger M, Kumlien G, Aschan J, et al. Risk-factors for moderate-to-severe chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 2002;8:674-682.
- Horowitz M, Gale R, Sondel P, et al. Graft-versus-leukemia reactions following bone marrow transplantation in humans. *Blood*. 1989;75:555-562.
- Ringdén O, Labopin M, Gluckman E, et al. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis: Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Bone Marrow Transplant*. 1996;18:921-929.

21. Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation: IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). *Blood*. 2000;95:3702-3709.
22. Horan JT, Liesveld JL, Fernandez ID, et al. Survival after HLA-identical allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trials. *Bone Marrow Transplant*. 2003;32:293-298.
23. Bensinger W, Martin P, Clift R, et al. A prospective, randomised trial of peripheral blood stem cells (PBSC) or marrow (BM) for patients undergoing allogeneic transplantation for hematologic malignancies [abstract]. *Blood*. 1999;94:368a.
24. Carlens S, Ringdén O, Aschan J, et al. Risk factors in bone marrow transplant recipients with leukaemia: increased relapse risk in patients treated with ciprofloxacin for gut decontamination. *Clin Transplant*. 1989;12:84-92.
25. Gratwohl A, Hermans J, Apperly J, et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia: Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. *Blood*. 1995;86:813-818.
26. Bensinger WJ, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancer. *N Engl J Med*. 2001;344:175-181.
27. Gorin NC, Labopin M, Rocha V, et al. European Cooperative Group for Blood and Marrow Transplantation Acute Leukemia Working Party: Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukaemia: influence of dose and stem cell source shows better outcome with rich marrow. *Blood*. 2003;105:3043-3051.